Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

Study identifier:LB-001LT

ClinicalTrials.gov identifier:NCT05506254

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Long-term Follow-up Study of Patients in LogicBio Clinical Trials for Methylmalonic Acidemia Characterized by MMUT Mutations Who Received hLB-001

Medical condition

Methylmalonic Acidemia

Phase

Healthy volunteers

Study drug

hLB-001

Sex

All

Actual Enrollment

Study type

Observational

Age

N/A

Date

Study Start Date: 20 Jul 2022

Estimated Primary Completion Date: 31 Dec 2037

Estimated Study Completion Date: 31 Dec 2037

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2023 by LogicBio Therapeutics, Inc.

Collaborators

Alexion Pharmaceuticals, Inc.

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Patients who have previously received hLB-001	-

Contacts

Contact